ArticleBrain and behavior2026
Immune-Related Polyradiculoneuropathy Associated With Immune Checkpoint Inhibitors: A Comprehensive Case Series.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveImmune-related polyradiculoneuropathy (irPRN) is a rare but potentially severe neurological adverse event secondary to immune checkpoint inhibitors (ICIs), closely resembling Guillain-Barré syndrome. This study aims to characterize the clinical presentation, neurophysiological findings, therapeutic strategies, and clinical outcomes of patients diagnosed with irPRN.
methodsWe conducted a retrospective single-center study including patients diagnosed with irPRN following ICI therapy between May 2018 and July 2024. Clinical, electrophysiological, and cerebrospinal fluid (CSF) data were analyzed.
resultsNine patients (mean age 67.9 years; 66.7% male) developed immune-related polyradiculoneuropathy (irPRN), with a median onset of 6 weeks following initiation of immune checkpoint inhibitors (ICIs). Most cases (66.7%) occurred in patients receiving anti-PD-1 monotherapy. The clinical presentation was characterized by symmetric limb weakness (100%) and sensory disturbances (88.9%). Electrodiagnostic studies demonstrated a demyelinating polyradiculoneuropathy in 8 of 9 patients; only one exhibited an axonal pattern. CSF analysis revealed elevated protein levels in all tested patients, with mild pleocytosis in 62.5%. At nadir, the modified Rankin Scale (mRS) ranged from 3 to 5. Immunomodulatory therapy was administered in 8 of 9 patients (88.9%), leading to notable functional improvement (mRS 1-2) in five cases. ICI rechallenge was attempted in two patients, neither of whom experienced recurrence. No deaths were directly attributed to irPRN.
conclusionIrPRN is a rare but distinct complication of ICI therapy, typically presenting with a demyelinating neurophysiological pattern and favorable response to immunotherapy. Early recognition and treatment are critical to improving functional outcomes. Rechallenge may be feasible in selected cases without recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.